AbbVie Stock Is Just What the Doctor Ordered [Yahoo! Finance]
Value Line, Inc. (VALU)
US:NASDAQ Investor Relations:
valueline.com/about/investorrelation.aspx
Company Research
Source: Yahoo! Finance
ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating ABBV a “Buy” or “Strong Buy” and price targets suggesting further upside. Today's Featured Stock Valued at $394 billion, AbbVie (ABBV) has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and Crohn's disease. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica, and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. More News from Barchart Warren Buffett Says Don't Bother Investing in Companies Solving Hard Problems, ‘What We Have Learned Is to Avoid Them'
Show less
Read more
Impact Snapshot
Event Time:
VALU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALU alerts
High impacting Value Line, Inc. news events
Weekly update
A roundup of the hottest topics
VALU
News
- Value Line (NASDAQ:VALU) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Value Line (NASDAQ:VALU) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- VALUE LINE, INC. ANNOUNCES STOCK REPURCHASE PROGRAMGlobeNewswire
- VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHAREGlobeNewswire
- Value Line, Inc. (VALU) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
VALU
Sec Filings
- 10/29/25 - Form 8-K
- 10/10/25 - Form 8-K
- 9/15/25 - Form 10-Q
- VALU's page on the SEC website